New Drugs of 2014: Part 2

Pharmacy Times, February 2015 Autoimmune Disorders, Volume 81, Issue 2

After completing this continuing education program, participants should be able to assess the clinical indications for new drugs approved by the FDA in 2014.

New Drugs of 2014: Part 2

Michael A. Mancano, PharmD

Clinical Professor of Pharmacy Practice

Chair, Department of Pharmacy Practice

Temple University School of Pharmacy

Philadelphia, Pennsylvania

Clinical Consultant

Pennsylvania Hospital

Department of Pharmacy

Philadelphia, Pennsylvania

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Assess the clinical indications for new drugs approved by the FDA in 2014.
  • Review the various mechanisms of action of the drugs discussed in this program.
  • Discuss the clinically relevant drug interactions for the drugs reviewed in this program.
  • Identify the most common adverse reactions for the new drugs approved in 2014.
  • Explain the approved dosing guidelines and recommended dose adjustments for the drugs reviewed.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: February 6, 2015

Expiration date: February 6, 2017

Estimated time to complete activity: 2.0 hours

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-008-H04-P. The activity is available for CE credit through February 6, 2017.